Neuroscience company Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) disclosed on Monday that it has commenced a Phase 2 clinical trial for ACP-204, targeting hallucinations and delusions linked to Alzheimer's disease psychosis (ADP).
Over 6.5 million Americans with Alzheimer's face psychosis, affecting 30%. The company's global Phase 2 trial includes 318 patients assessing ACP-204 doses (30 mg and 60 mg) versus placebo, focusing on the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales (SAPS-H+D) total score at Week 6.
This trial seamlessly transitions into two Phase 3 studies, each enrolling about 378 ADP patients. Participants completing the study may join a long-term open-label extension.
Alzheimer's disease psychosis, impacting 30% of AD patients, lacks FDA-approved drugs. ACP-204, an inverse agonist at the 5-HT2A receptor, addresses this unmet medical need, highlighting Acadia's commitment to advancing neuroscience breakthroughs for conditions like schizophrenia, Prader-Willi syndrome and neuropsychiatric symptoms in CNS disorders.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member